Citigroup
TXMD icon

Citigroup’s TherapeuticsMD TXMD Stock Holding History

Citigroup’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$2 – 6413
2025
Q4 		$2 Hold
1
– – ﹤0.01% 5942
2025
Q3 		$1 Sell
1
-202
-100% -$226 ﹤0.01% 6046
2025
Q2 		$235 Buy
+203
New +$246 ﹤0.01% 5471
2022
Q3 		– Sell
-69
Closed -$1K – 6333
2022
Q2 		$1K Sell
69
-390
-85% -$3.72K ﹤0.01% 6101
2022
Q1 		$9K Sell
459
-1,798
-80% -$28.3K ﹤0.01% 5594
2021
Q4 		$40K Buy
2,257
+697
+45% +$20.9K ﹤0.01% 5180
2021
Q3 		$58K Sell
1,560
-680
-30% -$30.2K ﹤0.01% 4661
2021
Q2 		$133K Sell
2,240
-21,044
-90% -$1.27M ﹤0.01% 4414
2021
Q1 		$1.56M Buy
23,284
+19,007
+444% +$1.49M ﹤0.01% 2659
2020
Q4 		$259K Buy
4,277
+1,649
+63% +$113K ﹤0.01% 4790
2020
Q3 		$208K Sell
2,628
-3,078
-54% -$245K ﹤0.01% 4592
2020
Q2 		$357K Sell
5,706
-1,288
-18% -$75K ﹤0.01% 4557
2020
Q1 		$371K Buy
6,994
+1,637
+31% +$162K ﹤0.01% 4160
2019
Q4 		$649K Buy
5,357
+1,919
+56% +$276K ﹤0.01% 4183
2019
Q3 		$624K Buy
3,438
+2,690
+360% +$379K ﹤0.01% 4132
2019
Q2 		$98K Sell
748
-79
-10% -$14.2K ﹤0.01% 5893
2019
Q1 		$202K Buy
827
+44
+6% +$11.6K ﹤0.01% 5089
2018
Q4 		$150K Buy
783
+622
+386% +$152K ﹤0.01% 5297
2018
Q3 		$53K Sell
161
-319
-66% -$97.7K ﹤0.01% 6479
2018
Q2 		$150K Buy
480
+109
+29% +$33.3K ﹤0.01% 5344
2018
Q1 		$90K Sell
371
-27
-7% -$7.57K ﹤0.01% 5705
2017
Q4 		$121K Buy
398
+332
+503% +$92.4K ﹤0.01% 5481
2017
Q3 		$18K Sell
66
-89
-57% -$25.7K ﹤0.01% 6486
2017
Q2 		$41K Sell
155
-1,983
-93% -$497K ﹤0.01% 5922
2017
Q1 		$770K Sell
2,138
-1,907
-47% -$590K ﹤0.01% 3486
2016
Q4 		$1.17M Buy
4,045
+3,631
+877% +$1.13M ﹤0.01% 3517
2016
Q3 		$140K Sell
414
-79
-16% -$28.9K ﹤0.01% 4955
2016
Q2 		$209K Sell
493
-1,902
-79% -$784K ﹤0.01% 4459
2016
Q1 		$767K Buy
2,395
+1,597
+200% +$545K ﹤0.01% 3650
2015
Q4 		$413K Buy
798
+778
+3,890% +$287K ﹤0.01% 4057
2015
Q3 		$6K Sell
20
-33
-62% -$11.7K ﹤0.01% 6660
2015
Q2 		$21K Sell
53
-87
-62% -$30.7K ﹤0.01% 6077
2015
Q1 		$43K Sell
140
-264
-65% -$64.4K ﹤0.01% 5621
2014
Q4 		$90K Buy
404
+329
+439% +$67.9K ﹤0.01% 5316
2014
Q3 		$17K Buy
75
+58
+341% +$14.6K ﹤0.01% 5999
2014
Q2 		$4K Sell
17
-276
-94% -$61.4K ﹤0.01% 6553
2014
Q1 		$92K Sell
293
-539
-65% -$172K ﹤0.01% 5066
2013
Q4 		$217K Buy
832
+830
+41,500% +$182K ﹤0.01% 4587
2013
Q3 		$0 Sell
2
-1,323
-100% -$160K ﹤0.01% 6985
2013
Q2 		$201K Buy
+1,325
New +$182K ﹤0.01% 4264

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup's TXMD Position: Q1 2026 in Review

Citigroup sold out of TherapeuticsMD (TXMD) in Q1 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in TXMD in Q2 2013 and held it in 40 quarters. The position peaked at $1.56M in Q1 2021. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • Citigroup reported no remaining TherapeuticsMD position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 TherapeuticsMD share in Q1 2026, an estimated $2.
  • Citigroup first reported a position in TherapeuticsMD in Q2 2013 and held it in 40 quarters.
  • Citigroup's TherapeuticsMD position peaked at $1.56M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.